Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
Healthcare
$5.75 +1.31%
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
52W Low $0.72High $20.32
Volume 0.07M
Average 0.62M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$7.32M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$17.03M
FY 2025 · Annual
+2776.7% YoYCash Flow Statement
USD
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.19M) |
| Depreciation & Amortization | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| Deferred Income Tax | (3.31M) | (2.38M) | (308K) | 0 | 0 |
| Stock-Based Compensation | 3.2M | 2.26M | 1.25M | 537.49K | 729.64K |
| Change in Working Capital | (3.64M) | 2.89M | 308K | 571.07K | (985.65K) |
| Accounts Receivables | (3.23M) | 2.03B | 562.77K | 356.34K | (377.99K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (124.72K) | 882.84K | (556.27K) | 0 | 0 |
| Other Working Capital | (281.36K) | (2.03B) | 301.5K | 214.73K | (607.67K) |
| Other Non-Cash Items | 3.31M | 2.38M | 308K | (14.77K) | 0 |
| Operating Cash Flow | (13.66M) | (12.28M) | (6.64M) | (4.89M) | (7.32M) |
| Capital Expenditures | (6.15K) | (5.66K) | 3 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (3) | 0 | 0 |
| Investing Cash Flow | (6.15K) | (5.66K) | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | (29.53K) | 0 |
| Common Stock Issued | 14.17M | 11.63M | 4.83M | 621.56K | 17.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 14.17M | 11.63M | 4.83M | 592.03K | 17.03M |
| Effect of Forex Changes | 121.9K | (93.01K) | 76.85K | (25.9K) | 46.22K |
| Net Change in Cash | 625.56K | (748.34K) | (1.73M) | (4.32M) | 9.75M |
| Free Cash Flow | (13.67M) | (12.28M) | (6.64M) | (4.89M) | (7.32M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$7.2M
+ D&A$119.3K
+ Stock-Based Comp$729.6K
+ Deferred Tax$0
- Working Capital-$985.7K
+ Other Non-Cash$0
= Operating Cash Flow-$7.3M
- Capex$0
= Free Cash Flow-$7.3M
Analysis
FY2025 free cash flow is -$7.3M. FCF conversion is 101.9% of net income. Operating cash flow was -$7.3M, with capex of $0. The largest bridge item is Working Capital at -$985.7K.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Aug 4, 2026 | |
| EFFECT | EFFECT filing | Jul 13, 2026 | |
| 424B3 | 424B3 filing | Jul 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 | |
| S-3 | S-3 filing | Jul 2, 2026 |
Does EDSA generate free cash flow?
Edesa Biotech, Inc. (EDSA) generated -$7.32M of free cash flow in fiscal 2025.
How much operating cash flow does EDSA produce?
Operating cash flow was -$7.32M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.